Tags

Type your tag names separated by a space and hit enter

Chlorhexidine prophylaxis for chemotherapy- and radiotherapy-induced stomatitis: a randomized double-blind trial.
Oral Surg Oral Med Oral Pathol 1990; 69(3):331-8OS

Abstract

Patients receiving cytotoxic antineoplastic therapy often have treatment-associated stomatitis. A 0.12% chlorhexidine digluconate mouthrinse was evaluated (15 ml, three times a day) in a prospective, double-blind randomized trial as prophylaxis against cytotoxic therapy-induced damage to oral soft tissues. Seventy subjects, forty inpatients receiving high-dose chemotherapy and thirty outpatients receiving high-dose head and neck radiation therapy, were evaluated. Chlorhexidine mouthrinse significantly reduced the incidence of oral mucositis in the chemotherapy group on day 14 (p less than 0.02) and at 1 week follow-up on day 28 (p less than 0.002). Mucositis in the patients undergoing chemotherapy who received chlorhexidine also resolved more rapidly. Mucositis severity was significantly less compared to the control chemotherapy group on day 14 (p less than 0.03), day 21 (p less than 0.04), and on 1 week follow-up (p less than 0.02). Concomitant trends in the reduction in oral streptococci and yeast were noted in the chemotherapy group receiving chlorhexidine mouthrinse. Although no differences were observed in oral mucositis between the control and chlorhexidine groups of patients undergoing high-dose radiotherapy, similar reductions of oral microflora to those seen in the chemotherapy population were also noted for patients undergoing radiation therapy who received chlorhexidine. Although generally not significant, some increase in gram-negative bacilli was noted in the chlorhexidine-treated patients in both the chemotherapy and radiotherapy groups, but there was no correlation with increased systemic infection. Prophylactic chlorhexidine mouthrinse reduces oral mucositis and microbial burden in patients with cancer undergoing intensive chemotherapy.

Authors+Show Affiliations

Department of Oral Health Practice, University of Kentucky, Lexington.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

2179802

Citation

Ferretti, G A., et al. "Chlorhexidine Prophylaxis for Chemotherapy- and Radiotherapy-induced Stomatitis: a Randomized Double-blind Trial." Oral Surgery, Oral Medicine, and Oral Pathology, vol. 69, no. 3, 1990, pp. 331-8.
Ferretti GA, Raybould TP, Brown AT, et al. Chlorhexidine prophylaxis for chemotherapy- and radiotherapy-induced stomatitis: a randomized double-blind trial. Oral Surg Oral Med Oral Pathol. 1990;69(3):331-8.
Ferretti, G. A., Raybould, T. P., Brown, A. T., Macdonald, J. S., Greenwood, M., Maruyama, Y., ... Ash, R. C. (1990). Chlorhexidine prophylaxis for chemotherapy- and radiotherapy-induced stomatitis: a randomized double-blind trial. Oral Surgery, Oral Medicine, and Oral Pathology, 69(3), pp. 331-8.
Ferretti GA, et al. Chlorhexidine Prophylaxis for Chemotherapy- and Radiotherapy-induced Stomatitis: a Randomized Double-blind Trial. Oral Surg Oral Med Oral Pathol. 1990;69(3):331-8. PubMed PMID: 2179802.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Chlorhexidine prophylaxis for chemotherapy- and radiotherapy-induced stomatitis: a randomized double-blind trial. AU - Ferretti,G A, AU - Raybould,T P, AU - Brown,A T, AU - Macdonald,J S, AU - Greenwood,M, AU - Maruyama,Y, AU - Geil,J, AU - Lillich,T T, AU - Ash,R C, PY - 1990/3/1/pubmed PY - 1990/3/1/medline PY - 1990/3/1/entrez SP - 331 EP - 8 JF - Oral surgery, oral medicine, and oral pathology JO - Oral Surg. Oral Med. Oral Pathol. VL - 69 IS - 3 N2 - Patients receiving cytotoxic antineoplastic therapy often have treatment-associated stomatitis. A 0.12% chlorhexidine digluconate mouthrinse was evaluated (15 ml, three times a day) in a prospective, double-blind randomized trial as prophylaxis against cytotoxic therapy-induced damage to oral soft tissues. Seventy subjects, forty inpatients receiving high-dose chemotherapy and thirty outpatients receiving high-dose head and neck radiation therapy, were evaluated. Chlorhexidine mouthrinse significantly reduced the incidence of oral mucositis in the chemotherapy group on day 14 (p less than 0.02) and at 1 week follow-up on day 28 (p less than 0.002). Mucositis in the patients undergoing chemotherapy who received chlorhexidine also resolved more rapidly. Mucositis severity was significantly less compared to the control chemotherapy group on day 14 (p less than 0.03), day 21 (p less than 0.04), and on 1 week follow-up (p less than 0.02). Concomitant trends in the reduction in oral streptococci and yeast were noted in the chemotherapy group receiving chlorhexidine mouthrinse. Although no differences were observed in oral mucositis between the control and chlorhexidine groups of patients undergoing high-dose radiotherapy, similar reductions of oral microflora to those seen in the chemotherapy population were also noted for patients undergoing radiation therapy who received chlorhexidine. Although generally not significant, some increase in gram-negative bacilli was noted in the chlorhexidine-treated patients in both the chemotherapy and radiotherapy groups, but there was no correlation with increased systemic infection. Prophylactic chlorhexidine mouthrinse reduces oral mucositis and microbial burden in patients with cancer undergoing intensive chemotherapy. SN - 0030-4220 UR - https://www.unboundmedicine.com/medline/citation/2179802/Chlorhexidine_prophylaxis_for_chemotherapy__and_radiotherapy_induced_stomatitis:_a_randomized_double_blind_trial_ L2 - https://medlineplus.gov/radiationtherapy.html DB - PRIME DP - Unbound Medicine ER -